Imaging · Contrast AgentRegulatory Approvalregulatorymid-term

FDA Grants Approval for Gadobutrol ANDA219146 by Zenara

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 6/21/2026, 6:31:27 AM

Assessment confidence: 84% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

The FDA's approval of Gadobutrol by Zenara signifies a new entrant in the contrast agent market, which could disrupt current pricing and market dynamics. Pharma strategy teams should closely monitor the competitive landscape as Zenara's market entry may lead to shifts in market share among established players. Regulatory context from FDA (FDA AP — GADOBUTROL (ORIG)) supports the near-term read. Assessment grounded in 19 ranked evidence items (16 high-relevance).

Strategic Assessment

Zenara's entry with Gadobutrol may impact pricing and market share dynamics among existing contrast agents. The strongest clinical anchor is Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT (ClinicalTrials.gov), moderate corpus alignment. In Imaging · Contrast Agent, 5 regulatory and 3 competitive items passed relevance filtering for Zenara.

Competitive Pressure

The most relevant competitive pressure comes from U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need (Pfizer) — sponsor/company relevance (pfizer). Secondary pressure from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment. This approval allows Zenara to enter the market for Gadobutrol, potentially increasing competition in the contrast agent segment.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — GADOBUTROL (ORIG) (FDA). Entity match (zenara); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval indicates a successful regulatory pathway for Zenara, which may prompt other companies to expedite their own applications for similar products, influencing the regulatory landscape.

Key Risks

Elevated medium regulatory exposure for Zenara could delay market entry or constrain labeling if agency review intensifies.
Clinical risk from ClinicalTrials.gov (Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study) could weigh on Zenara through efficacy or safety read-through uncertainty if follow-through weakens.

Key Opportunities

Zenara's introduction of Gadobutrol could lead to increased competition, potentially affecting pricing strategies and market share for existing contrast agents, impacting revenue streams.
Upside for Zenara may improve if Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone. (PubMed) delivers favorable follow-through.
Zenara's entry with Gadobutrol may impact pricing and market share dynamics among existing contrast agents.

What Would Change This Assessment

This becomes more urgent if Monitor market uptake of Gadobutrol and any competitive responses from established players in the imaging sector.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (zenara); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (ORIG)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (SUPPL)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — GADOBUTROL (SUPPL)
FDAhigh relevance
Entity match (gadobutrol); Regulatory pathway relevance (nda)
FDA document
View source
Clinical trials for medicines: modifying a clinical trial approval
MHRAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Positron Emission Tomography (PET) Imaging in People With Gaucher Mutations
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source
Evaluation of the Effectiveness of Physical Therapy for Low Back Pain According to Magnetic Resonance Imaging Findings
ClinicalTrials.govhigh relevance
Moderate corpus alignment
FDA document
View source

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
Pfizerhigh relevance
Sponsor/company relevance (Pfizer)
FDA document
View source
FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
FDA Grants Priority Review for TZIELD (Teplizumab) Supplement
Humanexa Signalsmedium relevance
Moderate corpus alignment

First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Contrasting dietary patterns remodel gut microbial function and generate multi-omic signatures associated with cardiometabolic markers.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Normalized periprostatic adipose tissue thickness: an imaging marker associated with prostate biopsy outcomes among patients with PI-RADS and PSA double gray zone.
PubMedhigh relevance
Moderate corpus alignment
FDA document
View source
Two-week essential oil inhalation treatment modulates the cortisol awakening response and improves self-reported symptoms in stressed adults.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Subacromial bursitis: current evidence and future directions in injection-based therapies-A narrative review.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Zenara
Gadobutrol
existing competitors in imaging

Commercial impact

medium

Zenara's introduction of Gadobutrol could lead to increased competition, potentially affecting pricing strategies and market share for existing contrast agents, impacting revenue streams.

Regulatory impact

medium

The approval indicates a successful regulatory pathway for Zenara, which may prompt other companies to expedite their own applications for similar products, influencing the regulatory landscape.

What to watch

Monitor market uptake of Gadobutrol and any competitive responses from established players in the imaging sector.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.